In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
29 authors.
Edward D B LopattoDepartment of Molecular Microbiology, Washington University in St. Louis, St. Louis, MO, USA.ORCID 0000-0002-6625-6143 Irina BasovaDepartment of Microbiology, University of Washington, Seattle, WA, USA.
Denise A SanickDepartment of Molecular Microbiology, Washington University in St. Louis, St. Louis, MO, USA.
Kevin O TamadonfarDepartment of Molecular Microbiology, Washington University in St. Louis, St. Louis, MO, USA.ORCID 0000-0002-6481-9993 Morgan R TimmDepartment of Molecular Microbiology, Washington University in St. Louis, St. Louis, MO, USA.ORCID 0000-0002-2947-9508 Jerome S PinknerDepartment of Molecular Microbiology, Washington University in St. Louis, St. Louis, MO, USA.ORCID 0000-0002-7389-7440 Karen W DodsonDepartment of Molecular Microbiology, Washington University in St. Louis, St. Louis, MO, USA.ORCID 0000-0001-7421-9660 Aaron J SchmitzDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0002-8077-6751 Ali H EllebedyDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0002-6129-2532 Mark J CartwrightWyss Institute, Harvard University, Boston, MA, USA.
Sarai BardalesWyss Institute, Harvard University, Boston, MA, USA.
Desmond WhiteWyss Institute, Harvard University, Boston, MA, USA.
Scott J HultgrenDepartment of Molecular Microbiology, Washington University in St. Louis, St. Louis, MO, USA.ORCID 0000-0001-8785-564X Funding
X-ray Scattering Technology CoreP30GM133893 · NIGMS · BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB · PI Vivian Stojanoff · 2019 to 2026
$38.6MUser Training and OutreachP30GM124165 · NIGMS · CORNELL UNIVERSITY · PI Nozomi Ando, J Christopher Fromme · 2018 to 2026
$34.2MUser Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Gregory L Hura · 2017 to 2026
$28.6MRational design and synthesis of small molecule inhibitors targeting unique pathogenic mechanisms in Gram- and Gram+ bacteria important in UTIU19AI157797 · NIAID · WASHINGTON UNIVERSITY · PI HULTGREN, SCOTT J. · 2021 to 2025
$11.4MCHAPERONE-ASSISTED PILI ASSEMBLY IN PATHOGENIC E. COLIR01AI029549 · NIAID · WASHINGTON UNIVERSITY · PI HULTGREN, SCOTT J., YUAN, PENG · 1991 to 2023
$5.7MAllosteric adhesins of enterobacterial pathogensR01AI171570 · NIAID · UNIVERSITY OF WASHINGTON · PI Rachel E Klevit, EVGENI Veniaminovic SOKURENKO · 2022 to 2026
$3.5MPathogenic Fiber Formation in Bacteria: Structural BasisR37AI048689 · NIAID · WASHINGTON UNIVERSITY · PI SCOTT J. HULTGREN · 2021 to 2026
$2.9MOptimization of protective antibodies response against bacterial adhesinsR21AI178593 · NIAID · UNIVERSITY OF WASHINGTON · PI CARTWRIGHT, MARK, SOKURENKO, EVGENI VENIAMINOVIC · 2023 to 2024
$485kInvestigating Novel Methods to Combat Urinary Tract InfectionsK99GM141364 · NIGMS · UNIVERSITY OF WASHINGTON · PI MAGALA, PEARL · 2022 to 2023
$225kNovel therapeutics for treatment of catheter-associated UTI and depletion of the vaginal reservoirF30DK135390 · NIDDK · WASHINGTON UNIVERSITY · PI TIMM, MORGAN ROSE WILT · 2023 to 2025
$123kNIAID NIH HHS R01 AI029549NIAID NIH HHS R01 AI171570NIAID NIH HHS R21 AI178593NIAID NIH HHS R37 AI048689NIAID NIH HHS U19 AI157797NIDDK NIH HHS F30 DK135390NIGMS NIH HHS K99 GM141364NIGMS NIH HHS P30 GM124165NIGMS NIH HHS P30 GM124169NIGMS NIH HHS P30 GM133893
6 · The paper itselfAbstract
The rise of multidrug-resistant bacterial infections necessitates the discovery of novel antimicrobial strategies. Here, we show that protein design provides a generalizable means of generating new antimicrobials by neutralizing the function of bacterial adhesins, which are virulence factors critical in host-pathogen interactions. We
Identifiers
PMID40894640
PMCPMC12393372
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390